The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

Dermatologists may also prescribe Otezla for people living with both psoriasis and psoriatic arthritis. They specialize in the care of patients with skin conditions, such as plaque psoriasis.

A new subgroup analysis reveals that adolescents with moderate-to-severe plaque psoriasis treated with once-daily icotrokinra ...

Plaque psoriasis (PsO) and psoriatic arthritis (PsA) are lifelong conditions that can have a significant impact on those diagnosed, particularly in their careers.

About one-third of psoriasis sufferers develop psoriatic arthritis, with swelling, tenderness and pain in joints, affecting daily activities and lifestyle. Psoriatic arthritis (PsA) is a chronic ...

Discover the signs of psoriatic arthritis, ... The characteristic psoriasis plaques appear as raised, red patches covered with silvery-white scales, most commonly on the elbows, ...

Medically reviewed by Anita C. Chandrasekaran, MD Psoriatic arthritis (PsA) is a chronic (long-lasting) condition that combines the skin-related symptoms of psoriasis with the joint-related ...

Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children ...

Psoriatic arthritis and burden of disease: Patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (Mapp) survey. Rheumatol Ther . 2016;3(1):91 ...

Over 80% of people diagnosed with psoriatic arthritis experience psoriasis first, ... with inflammation contributing to arterial plaque buildup. Additionally, ...

Dr. Michael Garshick discusses recently published recommendations for cardiovascular risk screening for patients with ...

Alongside the data in PsA, UCB will present at EULAR new results demonstrating that Bimzelx delivered sustained clinical responses up to three years in axSpA patients.